We are live on ! Find out more

PTHS

Pelthos Therapeutics

PTHS

Market cap $93.2M

24.35 USD

-0.01

0.04%

At close Updated Sep 4, 4:00 PM EDT

1 day

-0.04%

5 days

0.79%

1 month

-8.8%

3 months

-5.84%

6 months

5.82%

Year to date

-17.32%

1 year

-25.05%

5 years

-49.27%

10 years

-49.27%

About: Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

Employees: 92

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 71.4%

Negative 14.3%

Pelthos Therapeutics Q2 Earnings Call Highlights

Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed an accounting restatement related to the fair-value measurement of convertible debt and outlined expected 2027 launches for its complementary products XEPI and XEGLYZE.

Pelthos Therapeutics Q2 Earnings Call Highlights

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026.

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026.

Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.

Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative.

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Pelthos Therapeutics Q1 Earnings Call Highlights

Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.

Pelthos Therapeutics Q1 Earnings Call Highlights

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™